program-intro
The Opportunity of Chinese Medicine
In 2005, the output value of TCM in China was estimated at $15.60 billion (110.3 billion yuan). Tongjitang Chinese Medicine Company and Hutchison China MediTech Limited became the first TCM enterprises to list on the New York Stock Exchange and London Stock Exchange. Global awareness of health promotion and treatment of illnesses present ample opportunities for research & business development.

Bridging the Investment Gap
The 2008 SPARC Forum is the first-ever event in Hong Kong for Chinese medicine and herbal product companies to bridge the investment gap and capitalize on their research. It provides a unique platform for:

  • Gaining insight on the latest CM and herbal product research and innovations
  • Networking with leaders in the global CM and herbal product industry
  • Start-ups and established enterprises alike to meet with potential investors and business partners to commercialize their intellectual property
  • CM and herbal product innovators to explore technology partnership, licensing and other commercialization opportunity


    • Supporting Organizations
  • Venture capital and technology licensing associations
  • Chinese medicine industry-related associations
  • Universities
  • Research Institutes


    • Forum Program
  • Technology and product presentations by CM and herbal product innovators
  • Business leaders sharing experience, capitalizing on the latest technologies or market trends
  • Structured business matching activities
  • Networking events including luncheon, coffee/tea breaks and a cocktail reception
    • learn more